NDRA
Income statement / Annual
Last year (2023), ENDRA Life Sciences Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, ENDRA Life Sciences Inc.'s net income was -$10.06 M.
See ENDRA Life Sciences Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6,174.00
|
$351,622.00
|
$515,582.00
|
$1.41 M
|
$559,355.00
|
| Cost of Revenue |
$275,451.00 |
$234,258.00 |
$224,415.00 |
$165,249.00 |
$115,011.00 |
$0.00 |
$172,782.00 |
$235,878.00 |
$666,233.00 |
$259,145.00 |
| Gross Profit |
-$275,451.00 |
-$234,258.00 |
-$224,415.00 |
-$165,249.00 |
-$115,011.00 |
$6,174.00 |
$178,840.00 |
$279,704.00 |
$743,831.00 |
$300,210.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
1 |
0.51 |
0.54 |
0.53 |
0.54 |
| Research and Development
Expenses |
$5.00 M
|
$6.55 M
|
$5.48 M
|
$5.92 M
|
$6.57 M
|
$4.72 M
|
$1.93 M
|
$495,377.00
|
$1.04 M
|
$873,167.00
|
| General & Administrative
Expenses |
$4.70 M
|
$5.17 M
|
$4.94 M
|
$5.00 M
|
$3.86 M
|
$3.75 M
|
$2.75 M
|
$1.54 M
|
$1.22 M
|
$896,926.00
|
| Selling & Marketing
Expenses |
$820,554.00
|
$1.43 M
|
$1.08 M
|
$581,893.00
|
$412,434.00
|
$262,641.00
|
$122,604.00
|
$34,130.00
|
$50,635.00
|
$56,298.00
|
| Selling, General &
Administrative Expenses |
$5.52 M
|
$6.60 M
|
$6.02 M
|
$5.58 M
|
$4.27 M
|
$4.02 M
|
$2.87 M
|
$1.58 M
|
$1.27 M
|
$953,224.00
|
| Other Expenses |
$0.00 |
-$21,533.00 |
-$41,545.00 |
$8,842.00 |
-$106,903.00 |
-$777,253.00 |
$0.00 |
-$5,820.00 |
-$711,340.00 |
$0.00 |
| Operating Expenses |
$10.52 M |
$13.16 M |
$11.50 M |
$11.50 M |
$10.84 M |
$8.74 M |
$4.80 M |
$2.07 M |
$2.31 M |
$1.83 M |
| Cost And Expenses |
$10.52 M |
$13.16 M |
$11.50 M |
$11.50 M |
$10.84 M |
$8.74 M |
$4.98 M |
$2.31 M |
$2.98 M |
$2.09 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$232.43 |
$2,355.47 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$21,533.00 |
$0.00 |
$232,426.00 |
$2.36 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$275,451.00
|
$234,258.00
|
$224,415.00
|
$165,249.00
|
$115,011.00
|
$68,316.00
|
$61,481.00
|
$64,935.00
|
$72,225.00
|
$37,242.00
|
| EBITDA |
-$9.78 M
|
-$12.94 M
|
-$11.01 M
|
-$11.33 M
|
-$10.84 M
|
-$9.02 M
|
-$4.56 M
|
-$1.73 M
|
-$1.50 M
|
-$1.49 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
-1356.59 |
-10.85 |
-1.44 |
-0.56 |
-1.49 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
-1460.8
|
-13.16
|
-3.48
|
-1.11
|
-2.73
|
| Total Other
Income/Expenses Net |
$460,485.00
|
-$21,533.00
|
$267,055.00
|
-$223,584.00
|
-$2.46 M
|
-$777,253.00
|
-$750,904.00
|
-$983,610.00
|
-$710,635.00
|
-$654,697.00
|
| Income Before Tax |
-$10.06 M |
-$13.18 M |
-$11.23 M |
-$11.73 M |
-$13.31 M |
-$9.80 M |
-$5.38 M |
-$2.78 M |
-$2.28 M |
-$2.18 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
-1586.7
|
-15.29
|
-5.38
|
-1.62
|
-3.9
|
| Income Tax Expense |
$0.00 |
$21,533.00 |
-$41,545.00 |
$241,268.00 |
$2.25 M |
-$777,253.00 |
$750,904.00 |
$983,611.00 |
$710,633.00 |
$654,697.00 |
| Net Income |
-$10.06 M |
-$13.20 M |
-$11.19 M |
-$11.97 M |
-$15.55 M |
-$9.80 M |
-$5.38 M |
-$2.78 M |
-$2.28 M |
-$2.18 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
-1586.7 |
-15.29 |
-5.38 |
-1.62 |
-3.9 |
| EPS |
-1.11 |
-4.57 |
-5.47 |
-12.47 |
-41.48 |
-43.49 |
-39.01 |
-14.21 |
-11.67 |
-11.16 |
| EPS Diluted |
-1.11 |
-4.57 |
-5.47 |
-12.47 |
-41.48 |
-43.49 |
-39.01 |
-14.21 |
-11.67 |
-11.16 |
| Weighted Average Shares
Out |
$9.04 M
|
$2.89 M
|
$2.05 M
|
$959,611.00
|
$374,999.00
|
$225,243.00
|
$137,847.00
|
$195,351.00
|
$195,351.00
|
$195,351.00
|
| Weighted Average Shares
Out Diluted |
$9.04 M
|
$2.89 M
|
$2.05 M
|
$959,611.00
|
$374,999.00
|
$225,243.00
|
$195,751.00
|
$195,351.00
|
$195,351.00
|
$30,632.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
